Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Dr. Luke on Future Research With T-Cell Therapy in Melanoma

July 15th 2020

Jason J. Luke, MD, FACP, discusses the future of T-cell therapy in melanoma.

Postow Presents Progress Made in Melanoma

July 10th 2020

Immunotherapy and BRAF plus MEK inhibition are the key players in the treatment of patients with melanoma, Michael Postow, MD, said in a presentation during the 2020 ASCO Direct Highlights webcast.

Dr. Eggermont on Responses to Adjuvant Pembrolizumab in Stage III Melanoma Subtypes

July 9th 2020

Alexander M. M. Eggermont, MD, PhD, discusses responses to adjuvant pembrolizumab in patients with different subtypes of stage III melanoma.

Dr. Blank on Adjuvant Versus Neoadjuvant Approaches in Stage III Melanoma

July 8th 2020

Christian U. Blank, MD, PhD, discusses adjuvant versus neoadjuvant approaches in macroscopic stage III melanoma.

Adoptive Cell Therapy Aims to Improve Outcomes in Metastatic Melanoma

July 7th 2020

Lifleucel, a TIL therapy, is being investigated in patients with metastatic melanoma.

Optimal Sequence of Immunotherapy and Radiation Could Prolong Survival in Melanoma With Brain Metastases

July 6th 2020

A possible optimal sequence of radiation therapy and immune checkpoint inhibitors could help to prolong the survival of patients with melanoma who have brain metastases following surgical resection.

Neoadjuvant Nivolumab/Ipilimumab Improves RFS in Stage III Macroscopic Melanoma

June 24th 2020

The neoadjuvant combination of nivolumab and ipilimumab continues to demonstrate a benefit in RFS compared with the combination given in the adjuvant setting in patients with stage III macroscopic melanoma.

FDA Approves Pembrolizumab for Cutaneous Squamous Cell Carcinoma

June 24th 2020

The FDA has approved pembrolizumab (Keytruda) for patients with recurrent or metastatic cutaneous squamous cell carcinoma that is not curable by surgery or radiation.

Treatment Optimization for Patients With Melanoma

June 23rd 2020

Future Treatment Landscape for Melanoma

June 23rd 2020

Promising Late-Stage Trials in Melanoma

June 23rd 2020

Targeted Therapy Versus IO for Relapsed/Refractory Melanoma

June 23rd 2020

Novel Approaches for Relapsed/Refractory Melanoma

June 23rd 2020

Management of Brain Metastases in Melanoma

June 23rd 2020

I/O Dosing Schedules in Metastatic Melanoma

June 23rd 2020

Novel Therapies for Metastatic Melanoma

June 23rd 2020

Systemic Therapy for Metastatic Melanoma

June 23rd 2020

Adjuvant Therapy for Melanoma: Safety and Efficacy

June 23rd 2020

Adjuvant Therapy for Melanoma: Ongoing Studies of Interest

June 23rd 2020

Adjuvant Data Explored for Locally Advanced Melanoma

June 23rd 2020